1. Why Early-Stage Pricing & Reimbursement Feasibility is Essential

"The success of drug development extends far beyond achieving superior clinical trial results. Even the most innovative treatments may face significant delays or market entry barriers if they fail to demonstrate economic value within the complex landscape of the Korean National Health Insurance system. Conducting a pricing and reimbursement feasibility analysis during the early stages of development allows you to align your clinical trial design with the ultimate goal of reimbursement, proactively preventing 'evidence gaps' that often hinder market access. This is the most efficient risk-mitigation strategy to minimize unnecessary costs and time, while providing investors with a clear, value-driven roadmap to maximize your project’s success."  

2. How HyeRang Empowers Your Success
"HyeRang serves as a strategic compass for your business decisions, backed by our deep understanding of the Korean Health Insurance Review and Assessment Service (HIRA) and local reimbursement policies. Beyond mere analysis, we provide precision diagnostics on the potential gap between HIRA’s requirements and your current clinical and economic data. Composed of former market access professionals, our team offers specialized insights to support your 'Go/No-Go' decisions and develop optimized pricing strategies. By partnering with HyeRang, you ensure your therapeutic assets are positioned to gain maximum value in the Korean market, allowing your treatments to reach patients worldwide with greater speed and efficiency"